Vaccines, Blood & Biologics
-
MenHibrix
STN: BL 125363/0
Proper Name: Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine
Trade Name: MenHibrix
Manufacturer: GlaxoSmithKline Biologicals
Indication:
- Indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b for children 6 weeks of age through 18 months of age.
-
Supporting Documents
June 14, 2012 Summary Basis for Regulatory Action - MenHibrix (PDF - 154KB)June 14, 2012 Approval Letter - MenHibrix
Indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b. MenHibrix is approved for use in children 6 weeks of age through 18 months of age.Approval History, Letters, Reviews and Related Documents - MenHibrix
-
-
-
-
-
